Loading clinical trials...
Loading clinical trials...
Mosunetuzumab is a T-cell bispecific antibody targeting CD20 and CD3 aiming to redirect T cells to engage and eliminate malignant B cells. Bispecific antibodies (BsAb) are a promising treatment option...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
The Lymphoma Academic Research Organisation
Collaborators
NCT06549595 · Untreated Follicular Lymphoma
NCT03190928 · Follicular Lymphoma
NCT06191744 · Follicular Lymphoma (FL)
NCT06852638 · Renal Cancer, Renal Clear Cell Carcinoma, and more
NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Centre Hospitalier de La Cote Basque; Hematologie
Bayonne
Hopital Claude Huriez; Hematologie
Lille
Institut Paoli Calmettes
Marseille
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions